AVADEL PHARMACEUTICALS PLC (AVDL)

Data as of Feb 18, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch AVDL

See up to 3 months of AVDL. The 7-day demo opens the 1M and 3M ranges and puts AVDL on your watchlist.

Latest AVDL insider trades

Weiss Asset Management LP
Open-market sale$233.35M
Feb 13, 2026
Thomas S. McHugh - Officer
Open-market purchase$24K
Dec 13, 2024

About AVADEL PHARMACEUTICALS PLC (AVDL)

AVADEL PHARMACEUTICALS PLC is an SEC registrant, filing under CIK 0001012477, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.

Sector: Health Care

SEC filings for AVDL on EDGAR

AVDL Form 4 activity by transaction type, last 90 days

No Form 4 activity for AVDL in the last 90 days.

AVDL insider transactions (Form 4)

105

28 Form 4 filings on record, the earliest from Dec 10, 2024, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Feb 13, 2026	Weiss Asset Management LP	Open-market sale	Ordinary Shares	11,112,052	$21.00^{footnote F1}	$233.35M
Footnote F1 (price): Represents the cash portion of the consideration paid to shareholders upon the closing of the acquisition of the Issuer by Alkermes plc. In connection with such transaction, each outstanding share was automatically converted into the right to receive $21.00 per share in cash… Full note on SEC EDGAR
Feb 12, 2026	Susan Rodriguez - Officer	Derivative	Stock Option (Right to Buy)	300,000	-^{footnote F1,F2}	-
Footnote F1 (price): Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of… Full note on SEC EDGAR Footnote F2 (price): (continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and… Full note on SEC EDGAR
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Ordinary Shares	115,060^{footnote F3}	$21.00^{footnote F1,F2}	$2.42M
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Stock Option (Right to Buy)	60,000	-^{footnote F4}	-
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Stock Option (Right to Buy)	33,000	-^{footnote F4}	-
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Feb 12, 2026	Peter J. Thornton - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Ordinary Shares	23,496^{footnote F3}	$21.00^{footnote F1,F2}	$493K
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Stock Option (Right to Buy)	25,000	-^{footnote F4}	-
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Stock Option (Right to Buy)	30,000	-^{footnote F4}	-
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Stock Option (Right to Buy)	80,000	-^{footnote F4}	-
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Stock Option (Right to Buy)	47,500	-^{footnote F4}	-
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Stock Option (Right to Buy)	100,000	-^{footnote F4}	-
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Stock Option (Right to Buy)	125,000	-^{footnote F4}	-
Feb 12, 2026	Jerad G. Seurer - Officer	Derivative	Stock Option (Right to Buy)	84,000	-^{footnote F4}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Linda Palczuk - Director	Derivative	Ordinary Shares	78,905^{footnote F3}	$21.00^{footnote F1,F2}	$1.66M
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	60,000	-^{footnote F4}	-
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	33,000	-^{footnote F4}	-
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Feb 12, 2026	Linda Palczuk - Director	Derivative	Stock Option (Right to Buy)	25,000	-^{footnote F4}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Thomas S. McHugh - Officer	Derivative	Ordinary Shares	100,400^{footnote F3}	$21.00^{footnote F1,F2}	$2.11M
Feb 12, 2026	Thomas S. McHugh - Officer	Derivative	Stock Option (Right to Buy)	250,000	-^{footnote F4}	-
Feb 12, 2026	Thomas S. McHugh - Officer	Derivative	Stock Option (Right to Buy)	200,000	-^{footnote F4}	-
Feb 12, 2026	Thomas S. McHugh - Officer	Derivative	Stock Option (Right to Buy)	150,000	-^{footnote F4}	-
Feb 12, 2026	Thomas S. McHugh - Officer	Derivative	Stock Option (Right to Buy)	175,000	-^{footnote F4}	-
Feb 12, 2026	Thomas S. McHugh - Officer	Derivative	Stock Option (Right to Buy)	157,500	-^{footnote F4}	-
Feb 12, 2026	Thomas S. McHugh - Officer	Derivative	Stock Option (Right to Buy)	72,000	-^{footnote F4}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F5}	-
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F5}	-
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	33,000	-^{footnote F5}	-
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F5}	-
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F5}	-
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Ordinary Shares	22,000^{footnote F3}	$21.00^{footnote F1,F2}	$462K
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Ordinary Shares	67,025	$21.00^{footnote F1,F2}	$1.41M
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	60,000	-^{footnote F5}	-
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F5}	-
Feb 12, 2026	Mark Anthony McCamish - Director	Derivative	Stock Option (Right to Buy)	50,000	-^{footnote F5}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR Footnote F5 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Ordinary Shares	22,005^{footnote F3}	$21.00^{footnote F1,F2}	$462K
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Ordinary Shares	69,075	$21.00^{footnote F1,F2}	$1.45M
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Ordinary Shares	75,904	$21.00^{footnote F1,F2}	$1.59M
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Stock Option (Right to Buy)	60,000	-^{footnote F6}	-
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F6}	-
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F6}	-
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F6}	-
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Stock Option (Right to Buy)	33,000	-^{footnote F6}	-
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F6}	-
Feb 12, 2026	Geoffrey Michael Glass - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F6}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the… Full note on SEC EDGAR Footnote F6 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Eric J. Ende - Director	Derivative	Ordinary Shares	219,905^{footnote F3}	$21.00^{footnote F1,F2}	$4.62M
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	8,057	-^{footnote F4}	-
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	60,000	-^{footnote F4}	-
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	42,000	-^{footnote F4}	-
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	33,000	-^{footnote F4}	-
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Feb 12, 2026	Eric J. Ende - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Ordinary Shares	211,105^{footnote F3}	$21.00^{footnote F1,F2}	$4.43M
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Ordinary Shares	10,000	$21.00^{footnote F1,F2}	$210K
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	150,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	100,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	100,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	50,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	400,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	500,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	310,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	310,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	350,000	-^{footnote F5}	-
Feb 12, 2026	Gregory J. Divis - Officer	Derivative	Stock Option (Right to Buy)	600,000	-^{footnote F5}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the… Full note on SEC EDGAR Footnote F5 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 12, 2026	Naseem Amin - Director	Derivative	Ordinary Shares	22,000^{footnote F3}	$21.00^{footnote F1,F2}	$462K
Feb 12, 2026	Naseem Amin - Director	Derivative	Stock Option (Right to Buy)	49,500	-^{footnote F4}	-
Feb 12, 2026	Naseem Amin - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Feb 12, 2026	Naseem Amin - Director	Derivative	Stock Option (Right to Buy)	11,000	-^{footnote F4}	-
Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR
Feb 4, 2026	Mark Anthony McCamish - Director	Gift	Ordinary Shares	67,025	$0.00	-
Feb 4, 2026	Mark Anthony McCamish - Director	Gift	Ordinary Shares	67,025	$0.00	-
Sep 15, 2025	Linda Palczuk - Director	Gift	Stock Option (Right to Buy)	11,000	$0.00	-
Sep 15, 2025	Geoffrey Michael Glass - Director	Gift	Stock Option (Right to Buy)	11,000	$0.00	-
Jul 29, 2025	Mark Anthony McCamish - Director	Grant or award	Ordinary Shares	11,000	$0.00	-
Jul 29, 2025	Mark Anthony McCamish - Director	Grant or award	Stock Option (Right to Buy)	11,000	$0.00	-
Jul 29, 2025	Linda Palczuk - Director	Grant or award	Ordinary Shares	11,000	$0.00	-
Jul 29, 2025	Linda Palczuk - Director	Grant or award	Stock Option (Right to Buy)	11,000	$0.00	-
Jul 29, 2025	Peter J. Thornton - Director	Grant or award	Ordinary Shares	11,000	$0.00	-
Jul 29, 2025	Peter J. Thornton - Director	Grant or award	Stock Option (Right to Buy)	11,000	$0.00	-
Jul 29, 2025	Eric J. Ende - Director	Grant or award	Ordinary Shares	11,000	$0.00	-
Jul 29, 2025	Eric J. Ende - Director	Grant or award	Stock Option (Right to Buy)	11,000	$0.00	-
Jul 29, 2025	Geoffrey Michael Glass - Director	Grant or award	Ordinary Shares	11,000	$0.00	-
Jul 29, 2025	Geoffrey Michael Glass - Director	Grant or award	Stock Option (Right to Buy)	11,000	$0.00	-
Jul 29, 2025	Naseem Amin - Director	Grant or award	Ordinary Shares	11,000	$0.00	-
Jul 29, 2025	Naseem Amin - Director	Grant or award	Stock Option (Right to Buy)	11,000	$0.00	-
May 13, 2025	Susan Rodriguez - Officer	Grant or award	Stock Option (Right to Buy)	300,000	$0.00	-
Dec 24, 2024	Linda Palczuk - Director	Gift	Ordinary Shares	3,500	$0.00	-
Dec 17, 2024	Linda Palczuk - Director	Grant or award	Stock Option (Right to Buy)	25,000	$0.00	-
Dec 13, 2024	Thomas S. McHugh - Officer	Open-market purchase	Ordinary Shares	2,300	$10.44	$24K
Dec 11, 2024	Thomas S. McHugh - Officer	Open-market purchase	Ordinary Shares	5,000	$10.49	$52K
Dec 6, 2024	Gregory J. Divis - Officer	Open-market purchase	Ordinary Shares	9,598	$9.98	$96K
Dec 9, 2024	Gregory J. Divis - Officer	Open-market purchase	Ordinary Shares	402	$9.82	$4K
Dec 10, 2024	Geoffrey Michael Glass - Director	Open-market purchase	Ordinary Shares	10,075	$9.89	$100K
Dec 10, 2024	Geoffrey Michael Glass - Director	Open-market purchase	Ordinary Shares	10,204	$9.80	$100K
Dec 6, 2024	Linda Palczuk - Director	Open-market purchase	Ordinary Shares	3,000	$10.19	$31K

AVDL insider trading FAQ

What is the latest insider trade for AVDL?

AVADEL PHARMACEUTICALS PLC (AVDL) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-02-18. The full record for AVDL runs to 28 Form 4 filings, the earliest from 2024-12-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying AVDL stock?

No insider purchases of AVDL were filed in the last 90 days. 7 purchases are on record for this company.

How many insiders are selling AVDL stock?

No insider sales of AVDL were filed in the last 90 days. 1 sale is on record for this company.

Where can I see AVDL SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects AVDL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Feb 18, 2026 - Weiss Asset Management LP view on EDGAR
Feb 12, 2026 - Susan Rodriguez view on EDGAR
Feb 12, 2026 - Peter J. Thornton view on EDGAR
Feb 12, 2026 - Jerad G. Seurer view on EDGAR
Feb 12, 2026 - Linda Palczuk view on EDGAR
Feb 12, 2026 - Thomas S. McHugh view on EDGAR
Feb 12, 2026 - Mark Anthony McCamish view on EDGAR
Feb 12, 2026 - Geoffrey Michael Glass view on EDGAR
Feb 12, 2026 - Eric J. Ende view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where AVDL's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow AVDL with a 7-day demo

AVDL on your watchlist
Every AVDL Form 4 filing on record
Up to 3 months of AVDL price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Date

Insider

Transaction

Security

Price

Value

Feb 13, 2026

Weiss Asset Management LP

Open-market sale

Ordinary Shares

11,112,052

$21.00^{footnote F1}

$233.35M

Footnote F1 (price): Represents the cash portion of the consideration paid to shareholders upon the closing of the acquisition of the Issuer by Alkermes plc. In connection with such transaction, each outstanding share was automatically converted into the right to receive $21.00 per share in cash… Full note on SEC EDGAR

Feb 12, 2026

Susan Rodriguez - Officer

Derivative

Stock Option (Right to Buy)

300,000

-^{footnote F1,F2}

Footnote F1 (price): Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of… Full note on SEC EDGAR
Footnote F2 (price): (continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and… Full note on SEC EDGAR

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Ordinary Shares

115,060^{footnote F3}

$21.00^{footnote F1,F2}

$2.42M

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Stock Option (Right to Buy)

60,000

-^{footnote F4}

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Stock Option (Right to Buy)

33,000

-^{footnote F4}

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Feb 12, 2026

Peter J. Thornton - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Ordinary Shares

23,496^{footnote F3}

$21.00^{footnote F1,F2}

$493K

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Stock Option (Right to Buy)

25,000

-^{footnote F4}

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Stock Option (Right to Buy)

30,000

-^{footnote F4}

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Stock Option (Right to Buy)

80,000

-^{footnote F4}

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Stock Option (Right to Buy)

47,500

-^{footnote F4}

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Stock Option (Right to Buy)

100,000

-^{footnote F4}

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Stock Option (Right to Buy)

125,000

-^{footnote F4}

Feb 12, 2026

Jerad G. Seurer - Officer

Derivative

Stock Option (Right to Buy)

84,000

-^{footnote F4}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Linda Palczuk - Director

Derivative

Ordinary Shares

78,905^{footnote F3}

$21.00^{footnote F1,F2}

$1.66M

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

60,000

-^{footnote F4}

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

33,000

-^{footnote F4}

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Feb 12, 2026

Linda Palczuk - Director

Derivative

Stock Option (Right to Buy)

25,000

-^{footnote F4}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Thomas S. McHugh - Officer

Derivative

Ordinary Shares

100,400^{footnote F3}

$21.00^{footnote F1,F2}

$2.11M

Feb 12, 2026

Thomas S. McHugh - Officer

Derivative

Stock Option (Right to Buy)

250,000

-^{footnote F4}

Feb 12, 2026

Thomas S. McHugh - Officer

Derivative

Stock Option (Right to Buy)

200,000

-^{footnote F4}

Feb 12, 2026

Thomas S. McHugh - Officer

Derivative

Stock Option (Right to Buy)

150,000

-^{footnote F4}

Feb 12, 2026

Thomas S. McHugh - Officer

Derivative

Stock Option (Right to Buy)

175,000

-^{footnote F4}

Feb 12, 2026

Thomas S. McHugh - Officer

Derivative

Stock Option (Right to Buy)

157,500

-^{footnote F4}

Feb 12, 2026

Thomas S. McHugh - Officer

Derivative

Stock Option (Right to Buy)

72,000

-^{footnote F4}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F5}

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F5}

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

33,000

-^{footnote F5}

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F5}

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F5}

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Ordinary Shares

22,000^{footnote F3}

$21.00^{footnote F1,F2}

$462K

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Ordinary Shares

67,025

$21.00^{footnote F1,F2}

$1.41M

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

60,000

-^{footnote F5}

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F5}

Feb 12, 2026

Mark Anthony McCamish - Director

Derivative

Stock Option (Right to Buy)

50,000

-^{footnote F5}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR
Footnote F5 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Ordinary Shares

22,005^{footnote F3}

$21.00^{footnote F1,F2}

$462K

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Ordinary Shares

69,075

$21.00^{footnote F1,F2}

$1.45M

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Ordinary Shares

75,904

$21.00^{footnote F1,F2}

$1.59M

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Stock Option (Right to Buy)

60,000

-^{footnote F6}

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F6}

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F6}

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F6}

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Stock Option (Right to Buy)

33,000

-^{footnote F6}

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F6}

Feb 12, 2026

Geoffrey Michael Glass - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F6}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the… Full note on SEC EDGAR
Footnote F6 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Eric J. Ende - Director

Derivative

Ordinary Shares

219,905^{footnote F3}

$21.00^{footnote F1,F2}

$4.62M

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

8,057

-^{footnote F4}

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

60,000

-^{footnote F4}

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

42,000

-^{footnote F4}

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

33,000

-^{footnote F4}

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Feb 12, 2026

Eric J. Ende - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Ordinary Shares

211,105^{footnote F3}

$21.00^{footnote F1,F2}

$4.43M

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Ordinary Shares

10,000

$21.00^{footnote F1,F2}

$210K

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

150,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

100,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

100,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

50,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

400,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

500,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

310,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

310,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

350,000

-^{footnote F5}

Feb 12, 2026

Gregory J. Divis - Officer

Derivative

Stock Option (Right to Buy)

600,000

-^{footnote F5}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the… Full note on SEC EDGAR
Footnote F5 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR

Feb 12, 2026

Naseem Amin - Director

Derivative

Ordinary Shares

22,000^{footnote F3}

$21.00^{footnote F1,F2}

$462K

Feb 12, 2026

Naseem Amin - Director

Derivative

Stock Option (Right to Buy)

49,500

-^{footnote F4}

Feb 12, 2026

Naseem Amin - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Feb 12, 2026

Naseem Amin - Director

Derivative

Stock Option (Right to Buy)

11,000

-^{footnote F4}

Footnote F1 (price): Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders… Full note on SEC EDGAR
Footnote F3 (shares): Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective time, each Restricted Stock Award that was outstanding immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for… Full note on SEC EDGAR